Maze Therapeutics
MAZE
161 hedge funds and large institutions have $1.75B invested in Maze Therapeutics in 2026 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 66 increasing their positions, 38 reducing their positions, and 39 closing their positions.
108% more capital inflows, than outflows
Capital inflows: $452M | Capital outflows: $218M
74% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 38
1.8% more ownership
Funds ownership: 103.96% → 105.76% (+1.8%)
2% more call options, than puts
Call options by funds: $2.05M | Put options by funds: $2.01M
3% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 39
2% less funds holding
Funds holding: 165 → 161 (-4)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$68.2M |
| 2 |
Braidwell
Stamford,
Connecticut
|
+$29.9M |
| 3 |
BlackRock
New York
|
+$24.4M |
| 4 |
JP Morgan Chase
New York
|
+$23.7M |
| 5 |
Farallon Capital Management
San Francisco,
California
|
+$19.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Paradigm Biocapital Advisors
New York
|
-$81.9M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$24.4M |
| 3 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$22.4M |
| 4 |
Caligan Partners
New York
|
-$18.4M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$11.6M |
MAZE Hedge Fund Activity: Q2 2026 in Review
161 of the 8,359 institutional investors tracked by Wall St. Rank reported a position in Maze Therapeutics (MAZE) for Q2 2026, worth a combined $1.75B — up 13% from $1.54B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of MAZE and 38 opened new positions — a net loss of 1 holder — while 38 trimmed existing stakes and 66 added.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $68.2M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $81.9M sold.
- 161 institutional investors held Maze Therapeutics (MAZE) as of Q2 2026, down from 165 in Q1 2026.
- Funds reported $1.75B of Maze Therapeutics stock for Q2 2026, up 13% quarter-over-quarter.
- 38 funds opened new Maze Therapeutics positions in Q2 2026 and 39 closed out, a net change of -1 holder.
- The largest Maze Therapeutics buyer in Q2 2026 was T. Rowe Price Investment Management, an estimated $68.2M added.
- The largest Maze Therapeutics seller in Q2 2026 was Paradigm Biocapital Advisors, an estimated $81.9M sold.
Based on aggregated 13F filings for Q2 2026.